ESALY Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 saus. 2023 @ 22:59):

Stats
Šios dienos apimtis	331 859
Vidutinė apimtis	30 263.00
Rinkos kapitalizacija	17.64B
EPS	$31.81 ( 2022-12-30 )
Last Dividend	$0.570 ( 2022-09-28 )
Next Dividend	$0 ( N/A )
P/E	20.54
ATR14	$2.32 (3.77%)

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: -0.91 (very strong negative)

Signal:(39.154) Neutral

Eisai Co., Ltd. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Eisai Co., Ltd. Koreliacija - Valiuta/Žaliavos

0.73
( moderate )

0.33
( neutral )

-0.64
( weak negative )

0.76
( moderate )

-0.03
( neutral )

0.30
( neutral )

Eisai Co., Ltd. Finansinės ataskaitos

Annual	2022
Pajamos:	$756.23B
Bruto pelnas:	$581.40B (76.88 %)
EPS:	$159.44

FY	2022
Pajamos:	$756.23B
Bruto pelnas:	$581.40B (76.88 %)
EPS:	$159.44

FY	2021
Pajamos:	$645.94B
Bruto pelnas:	$484.63B (75.03 %)
EPS:	$146.95

FY	2020
Pajamos:	$695.62B
Bruto pelnas:	$519.93B (74.74 %)
EPS:	$425.01

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.570 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.34 - average (45.15%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.110	2010-03-28
Last Dividend	$0.570	2022-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	26	--
Total Paid Out	$20.43	--
Avg. Dividend % Per Year	0.00%	--
Score	1.89	--
Div. Sustainability Score	5.34
Div.Growth Potential Score	0
Div. Directional Score	2.09	--

Next Divdend (Est)
(2024-07-02)

$0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

1.89

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SYIEY	Ex Dividend Knight	2023-05-11	Annually	0.00%
HLFN	Ex Dividend Knight	2023-07-27	Quarterly	0.00%
ARKAY	Ex Dividend Junior	2023-05-11	Annually	0.00%
OSCUF	Ex Dividend Knight	2023-09-28	Annually	0.00%
DELKY	Ex Dividend Knight	2023-09-01	Quarterly	0.00%
TXHPF	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
JBSAY	Ex Dividend Junior	2023-06-29	Annually	0.00%
BKGFY	Ex Dividend Knight	2023-08-18	Semi-Annually	0.00%
RCBC	Ex Dividend Junior	2023-07-31	Quarterly	0.00%
ESALF	Ex Dividend Junior	2023-09-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0358	1.500	9.28	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0104	1.200	9.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0162	1.500	-0.931	-1.397	[0.1 - 1]
payoutRatioTTM	1.772	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.945	0.800	5.27	4.22	[1 - 3]
quickRatioTTM	0.858	0.800	9.66	7.73	[0.8 - 2.5]
cashRatioTTM	0.854	1.500	6.36	9.55	[0.2 - 2]
debtRatioTTM	0.120	-1.500	8.00	-10.00	[0 - 0.6]
interestCoverageTTM	7.68	1.000	8.27	8.27	[3 - 30]
operatingCashFlowPerShareTTM	-103.59	2.00	-10.00	-10.00	[0 - 30]
freeCashFlowPerShareTTM	-145.33	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0.194	-1.500	9.22	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.746	1.000	0.897	0.897	[0.2 - 0.8]
operatingProfitMarginTTM	0.0226	1.000	-1.547	-1.547	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.198	1.000	-2.21	-2.21	[0.2 - 2]
assetTurnoverTTM	0.289	0.800	-1.405	-1.124	[0.5 - 2]
Total Score				5.34

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	208.40	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0162	2.50	-0.599	-1.397	[0.1 - 1.5]
freeCashFlowPerShareTTM	-145.33	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-103.59	2.00	-10.00	-10.00	[0 - 30]
payoutRatioTTM	1.772	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-0.0478	1.500	-3.65	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0821	1.000	-4.55	0	[0.1 - 0.5]
Total Score				-1.153

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.